Gilead Sciences, an American biopharmaceutical company specializing in treatments for HIV infection, will establish a subsidiary in Romania next year to carry out marketing activities.
The subsidiary will begin marketing activities from January 1, 2022.
“Romania has become a particularly strategic country for Gilead, whose main goal is to provide innovative medical solutions to the needs of patients. In order to strengthen our partnership with all strategic partners in the health system, we establish our direct presence here, given that this proximity will bring added value to all involved, ”said Dr Sabine Tews, Director General of Eastern Europe, Executive Director of Gilead.
For more than 30 years, Gilead has been a leader in innovation in the field of HIV, contributing to advances in research, treatment, prevention, testing, and care for patients diagnosed with the disease. Antiretroviral treatments are used by several million people living with HIV.
Gilead has also administered four treatments for chronic hepatitis C virus and is one of the pioneers in transforming care for people with chronic hepatitis B virus.
Another segment in which the company is active is that of cancer treatments.
The company intends to bring to Romania several transformative therapies that address complex medical conditions in areas such as virology, oncology and inflammatory diseases.
Gilead operates in more than 35 countries around the world, with headquarters in Foster City, California.